In today’s fast-moving biotechnology landscape, breakthrough innovation rarely comes from one organisation alone. The most transformative discoveries, whether in gene therapies, AI-driven drug discovery, cell and gene manufacturing, or precision diagnostics, are emerging from collaborative ecosystems that bridge the strengths of academia, big pharma, and early-stage startups. As the
London, 11 Dec 2025: A major European clinical study, EASEE4YOU, is preparing to launch in the UK, with Great Ormond Street Hospital (GOSH) joining the international research effort. The study will investigate an emerging neurostimulation therapy designed for adolescents living with drug-resistant focal epilepsy. EASEE4YOU is assessing a minimally invasive
United Kingdom - 03 Dec 2025: Experts from Newcastle Hospitals, in collaboration with Newcastle University, have established the National Centre for Neurotechnology and Neurorestoration, the UK’s first dedicated facility for clinical trials involving advanced neurotechnologies. The new centre will support the development, testing, and implementation of cutting-edge technologies designed
United Kingdom - 01 Dec, 2025: The United States and the United Kingdom have reached a landmark agreement that will eliminate tariffs on British pharmaceutical products and medical technologies, marking a significant step toward strengthening transatlantic collaboration in life sciences. Under the deal, the UK will increase the net price
The biotechnology industry is in a transformative phase, propelled by recent, forward-looking regulatory updates across the UK and EU that make it easier to develop, manufacture and bring novel therapies to patients. As the demand for advanced therapeutics, precision medicine, and next-generation healthcare solutions continues to rise, the Medicines and